PM Modi hails scientists as India approves Covaxin, Covishield vaccines; Read his response

Prime Minister Narendra Modi congratulated the scientists & innovators of Bharat Biotech and Serum Institute of India (SII) after the Drug Controller General of India (DCGI) approved the ingeniously developed Covaxin and Oxford's Covishield for emergency use on Sunday. PM Modi hailed the approval of the vaccine as a 'decisive turning point' to strengthen a spirited fight against the coronavirus pandemic and congratulated India getting its first vaccine. READ | India Approves SII's Covishield & Bharat Biotech's Covaxin COVID Vaccines: DCGI Statement PM Modi lauds scientists as vaccines get DCGI nod Further, PM Modi pointed out that the approval given for the two vaccines Made in India will make every Indian proud and highlighted that it showed the eagerness of the scientific community in India to fulfil the dream of an Aatmanirbhar Bharat. PM Modi also reiterated gratitude to the doctors, medical staff, scientists, police personnel, sanitation workers and noted that the society will remain grateful to them for eternity. A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators. — Narendra Modi (@narendramodi) January 3, 2021 It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion. — Narendra Modi (@narendramodi) January 3, 2021 We reiterate our gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all Corona warriors for the outstanding work done, that too in adverse circumstances. We will remain eternally grateful to them for saving many lives. — Narendra Modi (@narendramodi) January 3, 2021 READ | 'Why?': Shah Mehmood Qureshi Says Pakistan PM Imran Khan Won't Resign On January 31 The massive development comes a day after the Subject Expert Committee (SEC) of the Central Drugs Standards Control Organisation (CDSCO) made recommendations to the Drugs Controller General of India to grant permission for restricted emergency use of the Serum Institute of India (SII) and Bharat Biotech's vaccines. As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of the accelerated approval process request of the SII, Bharat Biotech International Ltd as well as about phase-III trials of Cadila Healthcare Ltd. Here is the full DCGI statement: The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) met on 1st and 2nd January, 2021 and made recommendations in respect of proposal for Restricted Emergency Approval of COVID-19 virus vaccine of M/s Serum Institute of India and M/s Bharat Biotech as well as Phase III clinical trial of M/s Cadila Healthcare Ltd. The Subject Expert Committee consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine, etc. M/s Serum Institute of India, Pune has presented a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield) encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from AstraZeneca/Oxford University. The firm submitted safety, immunogenicity and efficacy data generated on 23,745 participants aged ≥ 18 years or older from overseas clinical studies. The overall vaccine efficacy was found to be 70.42%. Further, M/s Serum was granted permission to conduct Phase-II/III clinical trial on 1600 participants within the country. The firm also submitted the interim safety and immunogenicity data generated from this trial and the data was found comparable with the data from the overseas clinical studies. After detailed deliberations Subject Expert Committee has recommended for the grant of permission for restricted use in emergency situation subject to certain regulatory conditions. The clinical trial ongoing within the country by the firm will continue. M/s Bharat Biotech has developed a Whole Virion Inactivated Corona Virus Vaccine (Covaxin) in collaboration with ICMR and NIV (Pune), from where they received the virus seed strains. This vaccine is developed on Vero cell platform, which has well established track record of safety and efficacy in the country & globally. The firm has generated safety and immunogenicity data in various animal species such as mice, rats, rabbits, Syrian hamster, and also conducted challenge studies on non-human primates (Rhesus macaques) and hamsters. All these data has been shared by the firm with CDSCO. Phase I and Phase II clinical trials were conducted in approx.800 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response. The Phase III efficacy trial was initiated in India in 25,800 volunteers and till date, ~22,500 participants have been vaccinated across the country and the vaccine has been found to be safe as per the data available till date. The Subject Expert Committee (SEC) has reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue. M/s Cadila Healthcare Ltd., has developed a Novel Corona Virus-2019-nCov-Vaccine using DNA platform technology. The firm initiated Phase-I/II clinical trial in India in more than 1000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26000 Indian participants, which has been recommended by the Subject Expert Committee. M/s Serum and M/s Bharat Biotech vaccines have to be administered in two doses. All the three vaccines have to be stored at 2-8° C. After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial. READ | 'CM Jagan Betrayer Of Hindus; May Be Christian': Chandrababu Naidu Slams Idol Desecration READ | After Akhilesh Yadav's 'don't Trust Vaccine' Nonsense, Another SP Neta Makes Wilder Claim

Advertisement

PM Modi hails scientists as India approves Covaxin, Covishield vaccines; Read his response

PM Modi congratulated the scientists & innovators of Bharat Biotech & SII after the DCGI approved the emergency use of Covaxin & Covishield vaccines in India

Advertisement